Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Gross Profit (2021 - 2025)

Historic Gross Profit for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q3 2025 value amounting to $434.0 million.

  • Apellis Pharmaceuticals' Gross Profit rose 16584.13% to $434.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $903.0 million, marking a year-over-year increase of 4601.67%. This contributed to the annual value of $663.6 million for FY2024, which is 9629.73% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Gross Profit stood at $434.0 million, which was up 16584.13% from $164.9 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Gross Profit ranged from a high of $434.0 million in Q3 2025 and a low of $5.5 million during Q3 2021
  • In the last 5 years, Apellis Pharmaceuticals' Gross Profit had a median value of $88.0 million in 2023 and averaged $109.9 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Gross Profit tumbled by 6723.39% in 2022, and later skyrocketed by 54071.84% in 2023.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Gross Profit stood at $60.2 million in 2021, then tumbled by 67.23% to $19.7 million in 2022, then soared by 540.72% to $126.5 million in 2023, then soared by 35.75% to $171.7 million in 2024, then soared by 152.84% to $434.0 million in 2025.
  • Its last three reported values are $434.0 million in Q3 2025, $164.9 million for Q2 2025, and $132.4 million during Q1 2025.